FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies By Ogkologos - August 12, 2026 122 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Precision-T study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Bride’s Escorted Down Aisle By Dad Of Organ Donor Who Saved... October 11, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib November 22, 2021 Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... April 7, 2021 Melanoma Cells Are More Likely to Spread after a Stopover in... September 30, 2020 Load more HOT NEWS Remembering With Gratitude Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s... Women at High Risk of Breast Cancer Find it Hard to...
